Evolve BioSystems, Inc., a Davis, CA-based microbiotics company, completed a $9m Series A funding.
The round was led by Horizons Ventures with participation from seed investors including Tate and Lyle Ventures and a number of angels.
The company intends to use the capital for ongoing clinical activities, operational expansion, and preparations for commercial launch of its novel probiotic and prebiotic products.
Led by Dr. David Kyle, CEO, Evolve is developing novel solutions to resolve the dysbiosis in the human infant microbiome that can result from pre-term birth, Caesarian-Section deliveries, and exclusive use of infant formulae.
The company, which is a spin-out from the Foods For Health Institute (FFHI) at the University of California at Davis, closed a seed funding round in 2014 and is now undertaking multiple clinical trials to confirm the value of its proprietary prebiotic and probiotic assets in returning an infant’s microbiome to its naturally evolved state.